T Ploenes1, C Aigner2. 1. Abteilung für Thoraxchirurgie und thorakale Endoskopie, Universitätsmedizin Essen - Ruhrlandklinik, Tüschener Weg 40, 45239, Essen, Deutschland. 2. Abteilung für Thoraxchirurgie und thorakale Endoskopie, Universitätsmedizin Essen - Ruhrlandklinik, Tüschener Weg 40, 45239, Essen, Deutschland. clemens.aigner@rlk.uk-essen.de.
Abstract
BACKGROUND: Neuroendocrine tumors of the lungs are a very inhomogeneous group of malignancies. The surgical treatment should be adapted to the anatomical localization and histological subtype and individualized according to the functional reserve. MATERIAL AND METHODS: We performed a selective review of current literature, which was supplemented by personal experiences. RESULTS: The currently available outcome data are very inhomogeneous and depend on the histological subtype of neuroendocrine pulmonary tumors. A radical R0 resection is the key for an improvement in long-term overall and disease-free survival. CONCLUSION: Surgical treatment of carcinoid tumors is the current standard therapy. Sleeve resection should be performed, whenever possible. More aggressive tumors, such as large cell neuroendocrine carcinoma and small cell lung cancer should be treated in a multimodal concept.
BACKGROUND:Neuroendocrine tumors of the lungs are a very inhomogeneous group of malignancies. The surgical treatment should be adapted to the anatomical localization and histological subtype and individualized according to the functional reserve. MATERIAL AND METHODS: We performed a selective review of current literature, which was supplemented by personal experiences. RESULTS: The currently available outcome data are very inhomogeneous and depend on the histological subtype of neuroendocrine pulmonary tumors. A radical R0 resection is the key for an improvement in long-term overall and disease-free survival. CONCLUSION: Surgical treatment of carcinoid tumors is the current standard therapy. Sleeve resection should be performed, whenever possible. More aggressive tumors, such as large cell neuroendocrine carcinoma and small cell lung cancer should be treated in a multimodal concept.
Authors: Pier Luigi Filosso; Francesco Guerrera; Andrea Evangelista; Claudia Galassi; Stefan Welter; Erino Angelo Rendina; William Travis; Eric Lim; Inderpal Sarkaria; Pascal Alexandre Thomas Journal: Eur J Cardiothorac Surg Date: 2017-08-01 Impact factor: 4.191
Authors: Giuseppe Cardillo; Francesco Sera; Marco Di Martino; Paolo Graziano; Roberto Giunti; Luigi Carbone; Francesco Facciolo; Massimo Martelli Journal: Ann Thorac Surg Date: 2004-05 Impact factor: 4.330